CD274 and head and neck squamous cell carcinoma: To obtain further substantiation of their existence, we analyzed a dataset33 from a cohort of head and neck squamous cell carcinoma (HNSCC) patients treated with atezolizumab (anti-PD-L1), where tumor-infiltrating lymphocytes (TILs) were examined using mass flow cytometry (MC) (Fig. S3A).